Breast cancer is the most common cancer in women in developed countries, and the contribution of genetic susceptibility to breast cancer development has been well-recognized. However, a great proportion of these hereditary predisposing factors still remain unidentified. To examine the contribution of rare copy number variants (CNVs) in breast cancer predisposition, high-resolution genome-wide scans were performed on genomic DNA of 103 BRCA1, BRCA2, and PALB2 mutation negative familial breast cancer cases and 128 geographically matched healthy female controls; for replication an independent cohort of 75 similarly mutation negative young breast cancer patients was used. All observed rare variants were confirmed by independent methods. The stu...
Abstract A characteristic of sporadic and familial breast tumours is genomic instability, resulting ...
Copy number variants (CNVs) are a major source of genetic variation and can disrupt genes or affect ...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Abstract Breast cancer is the most common cancer in women in developed countries, and the contri...
<div><p>Breast cancer is the most common cancer in women in developed countries, and the contributio...
Breast cancer is the second most deadly cancer for New Zealand (NZ) women aged between 25-75 years. ...
BackgroundGermline copy number variants (CNVs) are pervasive in the human genome but potential disea...
Introduction: Genetic factors predisposing individuals to cancer remain elusive in the majority of p...
Germline copy number variants (CNVs) are pervasive in the human genome but potential disease associa...
Hereditary breast cancer accounts for 5-10% of all breast cancer cases. So far, known genetic risk f...
Introduction: Familial breast cancer (fBC) is generally associated with an early age of diagnosis an...
BACKGROUND: Women with breast cancer who have multiple affected relatives are more likely to have in...
A characteristic of sporadic and familial breast tumours is genomic instability, resulting from eith...
Copy number variants (CNVs) are a major source of genetic variation and can disrupt genes or affect ...
The identification of the two most prevalent susceptibility genes in breast cancer, BRCA1 and BRCA2,...
Abstract A characteristic of sporadic and familial breast tumours is genomic instability, resulting ...
Copy number variants (CNVs) are a major source of genetic variation and can disrupt genes or affect ...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...
Abstract Breast cancer is the most common cancer in women in developed countries, and the contri...
<div><p>Breast cancer is the most common cancer in women in developed countries, and the contributio...
Breast cancer is the second most deadly cancer for New Zealand (NZ) women aged between 25-75 years. ...
BackgroundGermline copy number variants (CNVs) are pervasive in the human genome but potential disea...
Introduction: Genetic factors predisposing individuals to cancer remain elusive in the majority of p...
Germline copy number variants (CNVs) are pervasive in the human genome but potential disease associa...
Hereditary breast cancer accounts for 5-10% of all breast cancer cases. So far, known genetic risk f...
Introduction: Familial breast cancer (fBC) is generally associated with an early age of diagnosis an...
BACKGROUND: Women with breast cancer who have multiple affected relatives are more likely to have in...
A characteristic of sporadic and familial breast tumours is genomic instability, resulting from eith...
Copy number variants (CNVs) are a major source of genetic variation and can disrupt genes or affect ...
The identification of the two most prevalent susceptibility genes in breast cancer, BRCA1 and BRCA2,...
Abstract A characteristic of sporadic and familial breast tumours is genomic instability, resulting ...
Copy number variants (CNVs) are a major source of genetic variation and can disrupt genes or affect ...
Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have repo...